The GenomicsDB is currently experiencing technical issues resulting in slow search speeds and gene/variant detail page loads. We are working to resolve this problem. Our apologies for any inconvenience.

Genomic Context

The genome browser snapshot is fully interactive. Mouse over track elements for more information. Click and drag to move tracks. Click and drag on top positional guide to zoom to a sub-region.

To add tracks, use the provided link to switch to the full genome browser view.

Gene-based Trait Associations

Back to Top

ADSP WES: Alzheimer's Disease ADSP

Results from gene-level rare and functional variant aggregation tests for association to AD supported by significane of p < 0.5 / #genes.

Individual score test statistics for rare, predicted functional, and loss of function variants colocated with the gene were aggregated to compute gene level p-values.

See NIAGADS Accession NG00065 for more information.

Back to Top
Accession Population N SNPs p-value Sign. Level rho CMAF CMAC Covariates Variant Filter Caveats
NG00065 European 18 3.3e-03 N/A 0 4.8e-03 100.2 PCs and sequencing center VEP MOD-HIGH N/A
NG00065 Meta 24 6.9e-03 N/A 0 0.010 224.3 PCs and sequencing center VEP MOD-HIGH N/A
NG00065 European 27 9.4e-03 N/A 0 3.4e-03 71.8 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes CADD > 20 N/A
NG00065 European 27 9.4e-03 N/A 0 3.4e-03 71.8 PCs and sequencing center CADD > 15 N/A
NG00065 European 27 9.4e-03 N/A 0 3.4e-03 71.8 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes CADD > 15 N/A
NG00065 European 27 9.4e-03 N/A 0 3.4e-03 71.8 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) CADD > 15 N/A
NG00065 European 27 9.4e-03 N/A 0 3.4e-03 71.8 PCs and sequencing center CADD > 20 N/A
NG00065 European 27 9.4e-03 N/A 0 3.4e-03 71.8 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) CADD > 20 N/A
NG00065 Meta 33 9.4e-03 N/A 0 9.0e-03 194.9 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes CADD > 20 N/A
NG00065 Meta 33 9.4e-03 N/A 0 9.0e-03 194.9 PCs and sequencing center CADD > 20 N/A
NG00065 Meta 33 9.4e-03 N/A 0 9.0e-03 194.9 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes CADD > 15 N/A
NG00065 Meta 33 9.4e-03 N/A 0 9.0e-03 194.9 PCs and sequencing center CADD > 15 N/A
NG00065 Meta 33 9.4e-03 N/A 0 9.0e-03 194.9 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) CADD > 20 N/A
NG00065 Meta 33 9.4e-03 N/A 0 9.0e-03 194.9 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) CADD > 15 N/A
NG00065 European 18 0.103 N/A 0 4.8e-03 100.2 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) VEP MOD-HIGH N/A
NG00065 European 18 0.120 N/A 1 4.8e-03 100.2 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes VEP MOD-HIGH N/A
NG00065 Meta 24 0.147 N/A 0 0.010 224.3 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) VEP MOD-HIGH N/A
NG00065 Meta 24 0.201 N/A 0 0.010 224.3 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes VEP MOD-HIGH N/A
NG00065 Caribbean Hispanic 1 0.353 N/A 0 1.3e-03 1.0 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes VEP HIGH
NG00065 Caribbean Hispanic 1 0.353 N/A 0 1.3e-03 1.0 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes LOF
NG00065 Caribbean Hispanic 7 0.360 N/A 1 0.015 11.8 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes VEP MOD-HIGH N/A
NG00065 Caribbean Hispanic 7 0.366 N/A 1 0.015 11.8 PCs and sequencing center VEP MOD-HIGH N/A
NG00065 Caribbean Hispanic 1 0.373 N/A 0 1.3e-03 1.0 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) VEP HIGH
NG00065 Caribbean Hispanic 1 0.373 N/A 0 1.3e-03 1.0 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) LOF
NG00065 Caribbean Hispanic 7 0.373 N/A 1 0.015 11.8 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) VEP MOD-HIGH N/A
NG00065 Caribbean Hispanic 1 0.377 N/A 0 1.3e-03 1.0 PCs and sequencing center VEP HIGH
NG00065 Caribbean Hispanic 1 0.377 N/A 0 1.3e-03 1.0 PCs and sequencing center LOF
NG00065 European 3 0.406 N/A 0 1.9e-04 4.1 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes VEP HIGH
NG00065 European 3 0.408 N/A 0 1.9e-04 4.0 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes LOF
NG00065 European 3 0.409 N/A 0 1.9e-04 4.1 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) VEP HIGH
NG00065 European 3 0.410 N/A 0 1.9e-04 4.0 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls) LOF
NG00065 European 3 0.420 N/A 0 1.9e-04 4.0 PCs and sequencing center LOF
NG00065 European 3 0.420 N/A 0 1.9e-04 4.1 PCs and sequencing center VEP HIGH
NG00065 Meta 4 0.445 N/A 1 2.3e-04 5.1 PCs and sequencing center VEP HIGH
NG00065 Meta 4 0.471 N/A 0 2.3e-04 5.1 PCs, sequencing center, sex, age at AD onset or last-known dementia-free age (for controls), and APOE E2 and E4 genotypes VEP HIGH
NG00065 Meta 4 0.487 N/A 0 2.3e-04 5.1 PCs, sequencing center, sex, and age at AD onset or last-known dementia-free age (for controls)